As 90% of all cases of squamous cell cancer of the head and neck (SCCHN) show (over-) expression of epidermal growth factor receptor (EGFR), there is a strong rationale supporting the targeting of EGFR in this malignancy. This rationale is further strengthened by the fact that EGFR overexpression is associated with a worse prognosis. Synergy between cetuximab and cisplatin was also observed in an A431 xenograft model. 
III clinical trials. Six of nine evaluable patients (67%) achieved major responses, including two complete responses (22%).
Cetuximab and Cisplatin in Recurrent and/or Metastatic Head and Neck CancerFirst-line Treatment
Bourhis et al. 9 enrolled 53 patients onto a phase I/II study of cetuximab (400mg/m 2 loading dose followed by weekly doses of 250mg/m 2 ) in combination with carboplatin at an area under the curve (AUC) of 5mg/ml.min or cisplatin 100mg/m 2 , administered every three weeks, each followed by a five-day infusion of 5-fluorouracil at escalating doses of 600, 800 and 1000mg/m 2 /day. The combination was well tolerated and a 5-fluorouracil dose of 1,000mg/m 2 /day was recommended for further studies. The overall response rate was 36%.
A summary of randomised phase III trials in recurrent/metastatic SCCHN is given in Table 1 . The Eastern Cooperative Oncology Group (ECOG) (Burtness et al. 10 ) assigned 123 patients (117 of whom were eligible and analysable) to 100mg/m 2 cisplatin every four weeks combined with weekly cetuximab (400mg/m 2 loading dose followed by weekly doses of 250mg/m 2 ) or placebo. Patients were stratified for performance status and disease status (previously treated or untreated). However, 30% of the patients in the cisplatin plus cetuximab arm versus 15% in the cisplatin plus placebo arm had received prior systemic therapy as either adjuvant or induction chemotherapy. The primary end-point of this study was progression-free survival (PFS).
The study was designed to detect with 90% power a difference in median PFS of two months between the cisplatin plus placebo arm and the cisplatin plus cetuximab arm (from two months to four months), using a one-sided log-rank test with an overall type I error rate of 0.025.
However, the observed median PFS in the control arm was higher than expected (2.7 months). As the median PFS for the cetuximab arm was 4.2 months, the difference did not reach statistical significance (p=0.09). Due to the longer PFS in the control arm, the power to detect a two-month difference in PFS was decreased to 50%. 10 Median overall survival was also not significantly different (9.2 versus 8 months;
p=0.21). However, the objective response rate was superior in the cisplatin/cetuximab arm (26 versus 10%; p=0.03). Interestingly, development of cetuximab-related skin toxicity was associated with an improved overall survival (hazard ratio 0.42; p=0.01).
In the EXTREME study (Vermorken et al. 11 ), 442 patients were randomised to 100mg/m 2 cisplatin or carboplatin at an AUC of 5mg/ml.min on day one followed by 1,000mg/m 2 /day 5-fluorouracil for four days alone or combined with weekly cetuximab (400mg/m 2 loading dose followed by weekly doses of 250mg/m 2 ). Cycles were repeated every three weeks to a maximum of six. In the combination arm, cetuximab was continued as a single agent until disease progression or unacceptable toxicity was observed. Patients with recurrent and/or metastatic SCCHN with measurable disease and a
Karnofsky score of at least 70 were eligible. All patients who had received prior chemotherapy were excluded from the study, except those who had received chemotherapy as part of their primary treatment for locally advanced disease, provided this chemotherapy was ended at least six months before inclusion in this trial. The primary end-point was overall survival. The study was designed to detect an increase in median survival from 7 to 9.5 months with 80% power at a 5% two-sided significance level. The EXTREME trial sepsis. There were 9 cases of grade 3 or 4 sepsis in the chemotherapy plus cetuximab group, and only 1 in the chemotherapy group (p=0.02).
The main additional grade 3 or 4 adverse events, including skin reactions, were consistent with the side-effect profile of cetuximab.
The addition of cetuximab did not have a negative impact on quality of life. Compliance with questionnaire completion was low at each time-point (≤50% post-baseline), although rates were higher in the cetuximab arm. 12 EGFR-inhibitor-induced skin toxicity can best be managed by adhering to widely accepted guidelines. 13 Thus far, no biomarkers predictive for sensitivity of SCCHN to EGFR inhibition have been identified. In the EXTREME study, EGFR gene copy number, as determined by fluorescent in situ hybridisation (FISH), was not a predictive biomarker for cetuximab efficacy. Head and Neck Cancer 
EGFR Tyrosine Kinases
Sensitising EGFR mutations in exon 19 or exon 21, which are strongly correlated with response to TKIs in non-small-cell lung cancer, are rarely detected in SCCHN. 4, [21] [22] [23] As can probably be expected, the activity of the EGFR TKIs gefitinib and erlotinib as single agents in SCCHN is modest, with overall response rates of less than 10% and a median overall survival of about six months. [24] [25] [26] Stewart et al. 26 randomly assigned 486 patients with metastatic or recurrent SCCHN to gefitinib 250 or 500mg/day or methotrexate 40mg/m 2 intravenously weekly. The median overall survival was 5.6, 6.0 and 6.7 months, respectively. The overall response rate was 2.7, 7.6 and 3.9%, respectively, with no statistically significant difference between either gefitinib arm or methotrexate.
Erlotinib was combined with cisplatin every three weeks in a phase I/II study conducted by the National Cancer Institute of Canada (NCI Canada) 27 in chemo-naïve patients with recurrent and/or metastatic SCCHN. The recommended phase II dose was erlotinib 100mg/day and cisplatin 75mg/m 2 . The overall response rate was 21% and the disease control rate was 70%. Median PFS and median overall survival were 3.3 and 7.9 months, respectively. The outcome was better in patients who developed skin rashes during cycle one.
Kim et al. 28 treated 50 patients with docetaxel 75mg/m 2 and cisplatin 75mg/m 2 intravenously every three weeks and erlotinib 150mg by mouth daily. Patients had had no previous EGFR therapy or chemotherapy for recurrent/metastatic disease. The overall response rate was 67% and the disease control rate was 95%. After a follow-up of 19 months, median overall survival was 11 months and PFS was six months. Two hundred and seventy patients were enrolled in a randomised, placebo-controlled phase III trial conducted by ECOG. 
Other Targeted Therapies
Multiple other targeted agents are under investigation in head and neck cancer. Thus far, disappointing results have been reported for most of them, including bortezomib, which inhibits the activation of nuclear factor kappa B (NF-κβ), 38 and dasatinib, which is a potent inhibitor of src-family kinases, ephA2, PDGFR, Abl and c-kit.
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Dual Pathway Inhibition
Dual pathway inhibition is gaining considerable interest, as inhibition of one pathway probably upregulates alternative pathway signalling.
Upregulation of VEGF has been implicated in resistance to EGFR inhibition. 40, 41 Cohen et al. 42 published promising results on the combined use of erlotinib and bevacizumab. Forty-eight patients with recurrent/metastatic SCCHN were treated with erlotinib 150mg/day and bevacizumab 15mg/kg every three weeks. Twenty-seven patients had received prior chemotherapy for recurrent/metastatic disease.
The combination was well tolerated, the most common side effects being rash and diarrhoea. 
